Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction

Rørth, Rasmus; Jhund, Pardeep S.; Mogensen, Ulrik M.; Kristensen, S L; Petrie, Mark C.; Køber, Lars; McMurray, John J.V.

doi:10.2337/dc17-2583

Cited by 43 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heart failure has become one of the major causes of CV death in individuals with diabetes, who are at high risk for heart failure and death [102,103]. The pathology of heart failure in diabetes is associated with cardiac remodeling caused by complexes of atherosclerotic coronary disease and diabetic cardiomyopathy, resulting in systolic and diastolic dysfunction [104][105][106].…”

Section: Cardiac Remodeling Modelsmentioning

confidence: 99%

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

Mori

Matsui

Hirano

et al. 2020

IJMS

View full text Add to dashboard Cite

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gut hormones that are secreted from enteroendocrine L cells and K cells in response to digested nutrients, respectively. They are also referred to incretin for their ability to stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner. Furthermore, GLP-1 exerts anorexic effects via its actions in the central nervous system. Since native incretin is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4), DPP-resistant GLP-1 receptor agonists (GLP-1RAs), and DPP-4 inhibitors are currently used for the treatment of type 2 diabetes as incretin-based therapy. These new-class agents have superiority to classical oral hypoglycemic agents such as sulfonylureas because of their low risks for hypoglycemia and body weight gain. In addition, a number of preclinical studies have shown the cardioprotective properties of incretin-based therapy, whose findings are further supported by several randomized clinical trials. Indeed, GLP-1RA has been significantly shown to reduce the risk of cardiovascular and renal events in patients with type 2 diabetes. However, the role of GIP in cardiovascular disease remains to be elucidated. Recently, pharmacological doses of GIP receptor agonists (GIPRAs) have been found to exert anti-obesity effects in animal models. These observations suggest that combination therapy of GLP-1R and GIPR may induce superior metabolic and anti-diabetic effects compared with each agonist individually. Clinical trials with GLP-1R/GIPR dual agonists are ongoing in diabetic patients. Therefore, in this review, we summarize the cardiovascular effects of GIP and GIPRAs in cell culture systems, animal models, and humans.

show abstract

Section: Cardiac Remodeling Modelsmentioning

confidence: 99%

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

Mori

Matsui

Hirano

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Already at that time authors remarked that "… excessive risk appears to be caused by factors other than accelerated atherogenesis and coronary heart disease", most probable cause being the recently described "diabetic cardiomyopathy" [7]. More than 4 decades passed by and situation is similar; with current estimates indicating a 2-to-4 fold increased risk of HF in T2DM subjects [8][9][10], both for the form with reduced ejection fraction (HFrEF) and that with preserved ejection fraction (HFpEF). The morbid association…”

Section: Heart Failure and Diabetes -Epidemiological Datamentioning

confidence: 99%

Editorial: Heart Failure in Type 2 Diabetes – The “Forgotten” Complication

Guja

Miulescu

2018

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

View full text Add to dashboard Cite

“…Type 2 diabetes is associated with an increased risk of incident HF. Among patients with asymptomatic LV dysfunction, which may be detected in as many as two‐thirds of patients with T2D, T2D is associated with a 30% increase in the risk of incident HF compared with patients without T2D . In patients with prevalent HF, T2D was associated with an increased risk of mortality .…”

Section: Epidemiology and Pathophysiology Of Type 2 Diabetes And Hearmentioning

confidence: 99%

Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure

Butler

Handelsman

Bakris

et al. 2020

European J of Heart Fail

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is associated with an increased risk of heart failure (HF), with recent reports indicating that HF with preserved ejection fraction (HFpEF) may be more common than HF with reduced ejection fraction (HFrEF) in patients with T2D. T2D and HF result in worse outcomes than either disease alone. Sodium–glucose co‐transporter‐2 inhibitors (SGLT‐2is) have significantly improved HF outcomes in patients with T2D and may represent a new therapeutic alternative for patients with T2D at risk for or with HF. Current guidelines recommend prevention of HF through risk factor management. Once developed, treatment of HFrEF should include neurohormonal and haemodynamic modulations; however, there are no specific treatments available for HFpEF. SGLT‐2is are the first class of glucose‐lowering therapy to prevent HF in clinical trials and real‐world studies in patients with T2D (with or without established cardiovascular disease and with or without baseline HF). Mechanistic studies suggest that SGLT‐2is have beneficial effects on both systolic and diastolic function and additional systemic effects that could benefit HF outcomes. In patients with HFrEF, SGLT‐2i treatment as add‐on to standard HF therapy has had beneficial effects on HF outcomes, irrespective of T2D status. These results and those of ongoing outcomes trials with SGLT‐2is may help establish this drug class as a treatment for HF in patients with HFrEF and HFpEF, as well as HF in patients without T2D.

show abstract

Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction

Abstract: Introduction: While it is well known that diabetes is common in prevalent heart failure (HF) and

Cited by 43 publications

References 31 publications

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

Editorial: Heart Failure in Type 2 Diabetes – The “Forgotten” Complication

Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure

Contact Info

Product

Resources

About